Email this article to a friend
Drotrecogin alfa (activated): current evidence supports treatment for severe sepsis patients with a high risk of death
-
* Corresponding author: Mark D Williams mardwill@lilly.com
Critical Care 2006, 10:424 doi:10.1186/cc5062
See related reply by Friedrich et al., http://ccforum.com/content/10/6/427, related commentary by Friedrich et al., http://ccforum.com/content/10/3/145, related letter by Agarwal and Nath, http://ccforum.com/content/10/4/416, related reply by Friedrich et al., http://ccforum.com/content/10/4/420 and related letter by Saxena and Williams, http://ccforum.com/content/10/5/422